Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Date:4/16/2008

ility of these unique compounds is with an oncology collaborator committed to initiating an NEI clinical program in the near-term."

Abstract 1591: "Mechanistic Analyses of the Therapeutic Activity of Nuclear Export Inhibitors (NEIs) in Cancer" presented data demonstrating a direct correlation between target (CRM1) occupancy and the downstream consequences of CRM1 inhibition, including nuclear export inhibition and cytotoxicity. Exposure of NEIs to cancer cell lines with normal (wild-type) p53 results in upregulation of p53, while only a transient upregulation of p53 is observed in normal cells exposed to NEIs. In cancer cell lines harboring PTEN mutations, NEI-induced nuclear entrapment of FOXO, which is regulated by the PTEN/PI3K/Akt pathway, is directly linked to the induction of apoptosis. NEIs induce apoptosis in tumor derived cell lines but not in normal cells, further confirming the hypothesis of the novel, potent and selective anticancer activity of NEIs.

Abstract 5688: "Anti-Tumor Activity of Novel Nuclear Export Inhibitors (NEIs) in Multiple Murine Leukemia Models" presented data from NEI compounds tested in murine models of leukemia, including acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) models. KOS-2464, Kosan's lead preclinical NEI compound induced marked and durable antitumor responses, including a doubling of survival in an orthotopic ALL model. KOS-2464 was well-tolerated at efficacious doses in all of the leukemia models tested.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tane
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...   Mary,s Medicinals today announced that its ... Sponsor of Operation Grow4Vets , a national, nonpartisan ... and services to assist them in living with injuries ... , An ever-increasing number of medical studies ... treatment for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic ...
(Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... and additional analyses from the Phase II portion of ... relaxin for the treatment of acute heart failure will ... meeting of the Heart Failure Association of the European ... M.D., professor of cardiology at the University of Brescia, ...
... Breast Cancer and Melanoma Studies - Conference Call to ... am BRANFORD, Conn., May 28 CuraGen Corporation ... for three data presentations from its ongoing clinical trials ... patients with advanced breast cancer and melanoma at the ...
Cached Medicine Technology:Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Recently, Fancyflyingfox.com, ... special occasion clothes, has announced its latest designs of ... addition, all the new elegant outfits are offered with ... place an order before October 30 can enjoy this ... and great marketing strategies, it has become one of ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... more than 600,000 people die of sudden cardiac arrest in ... heart attack or a heart rhythm disturbance. ,When medical ... in which the heart's main pumping chambers flutter wildly and ... survive to go home. ,About 30 percent of victims, ...
... sometimes switch to lower tar cigarettes in hopes of ... experience the consequences of higher tar cigarettes.// ,Non-filter cigarettes ... the United States and United Kingdom. A new study ... for people who smoke medium-tar cigarettes, low-tar cigarettes, or ...
... recent study researchers have created a model of the human ... may be a precursor to Alzheimer’s.// Myelin is ... allows for messages to be sent through the brain. However, ... promote the production of a toxic protein that attacks the ...
... destroys T-cells in the immune system. According to the ... 800,000 and 900,000 people living with HIV.// ,Previous ... be infected with HIV, and a new study helps ... of human foreskin. They found each sample contained cells ...
... doctors treat certain prostate cancer patients.The three strongest predictors ... grade, PSA level and pathologic stage. //The summation of ... system or a Gleason score (GS). The most common ... In a new study, researchers look to understand the ...
... molecule may have the potential to protect the kidneys ... ,For the study, mice were genetically engineered to ... factor (HGF) or another natural factor called parathyroid hormone-related ... functions, thus allowing the researchers to study how the ...
Cached Medicine News:Health News:Vasopressin Found To Boost Survival In Sudden Cardiac arrest 2Health News:New Hope for Kidney Failure 2
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Near point card/newspaper 8 to 48 point type 5 1/2" X 8"....
Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w...
... provides references to many common print sizes, from ... size. This provides the examiner a starting point ... with black ink on yellow styrene for increased ... 20/20. Other notations include Jaeger, M notation, lower ...
Medicine Products: